AI use case

Chai-2 AI Antibody Design Platform for Drug Discovery

Chai Discovery, founded in 2024, has quickly become one of the most well-funded biotech AI startups. In just over 12 months, the company raised over $225 million and announced a…

Browse catalog

At a glance

Core facts from this catalog record. Primary narrative lives in the hero above; full raw fields follow in the next section.

Company/Organization: Chai Discovery
Industry: Biotechnology
Location: San Francisco

Record fields

Every column from the source row, in stable order. URLs open in a new tab.

Title

Chai-2 AI Antibody Design Platform for Drug Discovery

Content

Chai Discovery, founded in 2024, has quickly become one of the most well-funded biotech AI startups. In just over 12 months, the company raised over $225 million and announced a partnership with Eli Lilly to help develop new medicines. The company's algorithm Chai-2 is designed to develop antibodies - the proteins necessary for fighting illnesses. Chai's ambition is to build the 'computer-aided design suite' for molecules. The company says Chai-2 is achieving significant improvements in success rates over other methods for de novo antibody design - building custom antibodies from scratch rather than modifying existing ones. Their latest models can design molecules that have properties suitable for actual drugs, tackling targets that have been out of reach with traditional methods.

URL

https://techcrunch.com/2026/01/16/from-openais-offices-to-a-deal-with-eli-lilly-how-chai-discovery-became-one-of-the-flashiest-names-in-ai-drug-development/

Continue exploring AI deployments in the catalog.

Back to use cases